
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is expected to have a positive outlook as it continues to generate strong results from its upcoming catalysts, including initiation of various trials and topline results in 2H26. These upcoming catalysts, along with Exelixis' current partnerships and expected FDA approval for zanzalintinib, make it a potential "pipeline-in-a-product" play with room for growth in the medullary thyroid, kidney, liver, and other cancer markets. Additionally, Exelixis' strong financial performance and increasing sales trajectory make it likely to outperform the market, as seen with its expected increase in price target to $55 (DCF-derived) from $50. Therefore, Exelixis presents a strong opportunity for investors seeking potential growth in the biopharmaceutical industry.
Bears say
Exelixis is facing several challenges that could negatively impact its financials and stock performance. These include a crowded market for its cancer treatments, with competition from established players and new entrants, and a low success rate for its early-stage pipeline programs. Despite strong cash generation and share repurchase programs, there is currently a lack of momentum drivers for the stock. Additionally, the company's recent data updates for its lead product, cabozantinib, have shown only modest improvements, raising doubts about its potential for sustained success.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares